Cy­to­ki­net­ics ax­es lead drug af­ter it im­plodes in a PhI­II mus­cle tri­al for ALS, shares crater

Cy­to­ki­net­ics $CYTK lead mus­cle drug has crashed in a Phase III study for ALS.

The biotech re­port­ed this morn­ing that tirasem­tiv, de­signed to amp up the mus­cles of sick pa­tients, failed to hit the pri­ma­ry end­point on what’s called slow vi­tal ca­pac­i­ty, which mea­sures how much air can be ex­haled. And now the ther­a­py is be­ing shelved as the biotech’s stock craters, plung­ing more than 30% Tues­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.